Literature DB >> 19021836

Impact of reperfusion after 3 hours of symptom onset on tissue fate in acute cerebral ischemia.

Oh Young Bang1, David S Liebeskind, Brian H Buck, Sa Rah Yoon, Jeffry R Alger, Bruce Ovbiagele, Jeffrey L Saver.   

Abstract

BACKGROUND: Reperfusion of penumbral tissue is a promising strategy for treatment of acute cerebral ischemia more than 3 hours from symptom onset. However, there has been only sparse direct evidence that reperfusion after 3 hours prevents infarct growth.
METHODS: We analyzed clinical and serial magnetic resonance imaging (MRI) data on patients who received endovascular recanalization therapy 3-12 hours after last known well time. Multimodal MRIs were acquired pretreatment, early (1-20 hours), and late (2-7 days) after treatment. Degree of recanalization was assessed on end of procedure catheter angiogram, degree of reperfusion on early posttreatment perfusion MRI, and infarct growth by analysis of diffusion lesion volumes on pretreatment and late MRIs.
RESULTS: Twenty-seven (12 men, 15 women) underwent endovascular recanalization procedures at 6.0 +/- 2.1 hours (range, 3.0-11.5 hours) after last known well time. Immediate posttreatment perfusion lesion (Tmax > or =4 seconds) volume correlated strongly with infarct growth (r= .951, P < .001), exceeding the correlations of vessel recanalization score (r=-.198, P= .446) and pretreatment diffusion-perfusion mismatch volume (r= .518, P= .033). Without reperfusion, enlargement of DWI lesion volume was observed in all patients, and extent of enlargement depended on volume of immediate posttreatment perfusion defects.
CONCLUSION: Our data indicate that posttreatment reperfusion is the major determinant of threatened tissue outcome, and suggest reperfusion even after 3 hours of symptom onset can alter tissue fate over a wide range of mismatch volumes.

Entities:  

Mesh:

Year:  2008        PMID: 19021836      PMCID: PMC2755618          DOI: 10.1111/j.1552-6569.2008.00303.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  20 in total

1.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study.

Authors:  Gregory W Albers; Vincent N Thijs; Lawrence Wechsler; Stephanie Kemp; Gottfried Schlaug; Elaine Skalabrin; Roland Bammer; Wataru Kakuda; Maarten G Lansberg; Ashfaq Shuaib; William Coplin; Scott Hamilton; Michael Moseley; Michael P Marks
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

2.  Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia.

Authors:  P D Schellinger; J B Fiebach; O Jansen; P A Ringleb; A Mohr; T Steiner; S Heiland; S Schwab; O Pohlers; H Ryssel; B Orakcioglu; K Sartor; W Hacke
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

3.  Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke.

Authors:  Robert A Felberg; Nicholas J Okon; Ashraf El-Mitwalli; W Scott Burgin; James C Grotta; Andrei V Alexandrov
Journal:  Stroke       Date:  2002-05       Impact factor: 7.914

4.  Perfusion-weighted magnetic resonance imaging thresholds identifying core, irreversibly infarcted tissue.

Authors:  Ludy C Shih; Jeffrey L Saver; Jeffry R Alger; Sidney Starkman; Megan C Leary; Fernando Vinuela; Gary Duckwiler; Y Pierre Gobin; Reza Jahan; J Pablo Villablanca; Paul M Vespa; Chelsea S Kidwell
Journal:  Stroke       Date:  2003-05-08       Impact factor: 7.914

5.  Ischemic stunning of the brain: early recanalization without immediate clinical improvement in acute ischemic stroke.

Authors:  Andrei V Alexandrov; Christiana E Hall; Lise A Labiche; Anne W Wojner; James C Grotta
Journal:  Stroke       Date:  2004-01-15       Impact factor: 7.914

6.  Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study.

Authors:  T Neumann-Haefelin; R du Mesnil de Rochemont; J B Fiebach; A Gass; C Nolte; T Kucinski; J Rother; M Siebler; O C Singer; K Szabo; A Villringer; P D Schellinger
Journal:  Stroke       Date:  2003-12-11       Impact factor: 7.914

7.  Late secondary ischemic injury in patients receiving intraarterial thrombolysis.

Authors:  Chelsea S Kidwell; Jeffrey L Saver; Sidney Starkman; Gary Duckwiler; Reza Jahan; Paul Vespa; J Pablo Villablanca; David S Liebeskind; Y Pierre Gobin; Fernando Vinuela; Jeffry R Alger
Journal:  Ann Neurol       Date:  2002-12       Impact factor: 10.422

Review 8.  Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging.

Authors:  Chelsea S Kidwell; Jeffry R Alger; Jeffrey L Saver
Journal:  Stroke       Date:  2003-10-23       Impact factor: 7.914

9.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

10.  Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours.

Authors:  J Röther; P D Schellinger; A Gass; M Siebler; A Villringer; J B Fiebach; J Fiehler; O Jansen; T Kucinski; V Schoder; K Szabo; G J Junge-Hülsing; M Hennerici; H Zeumer; K Sartor; C Weiller; W Hacke
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

View more
  1 in total

1.  Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator.

Authors:  J Puig; S Pedraza; A Demchuk; J Daunis-I-Estadella; H Termes; G Blasco; G Soria; I Boada; S Remollo; J Baños; J Serena; M Castellanos
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-08       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.